Home > Oncology > ASCO 2021 > Lung Cancer > Neoadjuvant nivolumab plus chemotherapy improves surgical outcomes in NSCLC

Neoadjuvant nivolumab plus chemotherapy improves surgical outcomes in NSCLC

Presented By
Dr Jonathan Spicer, McGill University, Canada
Conference
ASCO 2021
Trial
Phase 3, CheckMate 816
The results from CheckMate 816 showed that patients with resectable non-small cell lung cancer (NSCLC) who were treated with neoadjuvant nivolumab plus chemotherapy had improved pathologic complete response (pCR) rates and improved surgical outcomes. The randomised, phase 3 CheckMate 816 trial (NCT02998528) evaluates the efficacy and safety of neoadjuvant therapy with nivolumab plus chemotherapy in patients with resectable NSCLC. Recently, results were presented of the first primary endpoint (pCR, defined as 0% viable tumour cells in lung and lymph nodes): median pCR was 24% in patients (n=179) treated with neoadjuvant nivolumab plus chemotherapy versus 2.2% in patients (n=179) treated with neoadjuvant chemotherapy (HR 13.94; 95% CI 3.49–55.75; P<0.0001) [1]. At the ASCO 2021 Annual Meeting, Dr Jonathan Spicer (McGill Univ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on